Cargando…

Migraine progression in subgroups of migraine based on comorbidities: Results of the CaMEO Study

OBJECTIVE: To test the hypothesis that statistically defined subgroups of migraine (based on constellations of comorbidities and concomitant conditions; henceforth comorbidities), previously identified using Chronic Migraine Epidemiology and Outcomes (CaMEO) Study data, differ in prognosis, as measu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lipton, Richard B., Fanning, Kristina M., Buse, Dawn C., Martin, Vincent T., Hohaia, Lee B., Adams, Aubrey Manack, Reed, Michael L., Goadsby, Peter J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6937494/ https://www.ncbi.nlm.nih.gov/pubmed/31690685 http://dx.doi.org/10.1212/WNL.0000000000008589

Ejemplares similares

The impact of chronic migraine: The Chronic Migraine Epidemiology and Outcomes (CaMEO) Study methods and baseline results
por: Adams, Aubrey Manack, et al.
Publicado: (2015)

The Effect of Psychiatric Comorbidities on Headache‐Related Disability in Migraine: Results From the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study
por: Lipton, Richard B., et al.
Publicado: (2020)

Discontinuation of Acute Prescription Medication for Migraine: Results From the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study
por: Lipton, Richard B., et al.
Publicado: (2019)

Life With Migraine: Effects on Relationships, Career, and Finances From the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study
por: Buse, Dawn C., et al.
Publicado: (2019)

A Comparison of the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study and American Migraine Prevalence and Prevention (AMPP) Study: Demographics and Headache‐Related Disability
por: Lipton, Richard B., et al.
Publicado: (2016)

Characterizing opioid use in a US population with migraine: Results from the CaMEO study
por: Lipton, Richard B., et al.
Publicado: (2020)

Assessing Barriers to Chronic Migraine Consultation, Diagnosis, and Treatment: Results From the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study
por: Dodick, David W., et al.
Publicado: (2016)

Pre- and post-headache phases of migraine: multi-country results from the CaMEO – International Study
por: Lipton, Richard B., et al.
Publicado: (2023)

Optimized Acute Treatment of Migraine Is Associated With Greater Productivity in People With Migraine: Results From the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study
por: Buse, Dawn C., et al.
Publicado: (2023)

Medication Overuse and Headache Burden: Results From the CaMEO Study
por: Schwedt, Todd J., et al.
Publicado: (2021)

Family Impact of Migraine: Development of the Impact of Migraine on Partners and Adolescent Children (IMPAC) Scale
por: Lipton, Richard B., et al.
Publicado: (2017)

Comorbid pain and migraine chronicity: The Chronic Migraine Epidemiology and Outcomes Study
por: Scher, Ann I., et al.
Publicado: (2017)

Defining the Differences Between Episodic Migraine and Chronic Migraine
por: Katsarava, Zaza, et al.
Publicado: (2011)

EHMTI-0099. Migraineur perception regarding family burden from chronic migraine: results of the CAMEO (chronic migraine epidemiology & outcomes) study
por: Buse, DC, et al.
Publicado: (2014)

Depression and risk of transformation of episodic to chronic migraine
por: Ashina, Sait, et al.
Publicado: (2012)

Effects of onabotulinumtoxinA treatment for chronic migraine on common comorbidities including depression and anxiety
por: Blumenfeld, Andrew M, et al.
Publicado: (2019)

Acute treatment optimization for migraine: results of the American migraine prevalence and prevention (AMPP) study
por: Lipton, RB, et al.
Publicado: (2013)

Comorbid and co-occurring conditions in migraine and associated risk of increasing headache pain intensity and headache frequency: results of the migraine in America symptoms and treatment (MAST) study
por: Buse, Dawn C., et al.
Publicado: (2020)

Fluctuations in episodic and chronic migraine status over the course of 1 year: implications for diagnosis, treatment and clinical trial design
por: Serrano, Daniel, et al.
Publicado: (2017)

Most Bothersome Symptom in Persons With Migraine: Results From the Migraine in America Symptoms and Treatment (MAST) Study
por: Munjal, Sagar, et al.
Publicado: (2019)

EHMTI-0169. Trajectories of headache days over one year (5 waves) in chronic and episodic migraineurs participating in the chronic migraine epidemiology and outcomes (cameo) study
por: Lipton, RB, et al.
Publicado: (2014)

Major life events, stress appraisal, and migraine: results of the American Migraine Prevalence and Prevention (AMPP) study
por: Manack, AN, et al.
Publicado: (2013)

Multimodal Migraine Management and the Pursuit of Migraine Freedom: A Narrative Review
por: Blumenfeld, Andrew M., et al.
Publicado: (2023)

Factors associated with acute medication overuse in people with migraine: results from the 2017 migraine in America symptoms and treatment (MAST) study
por: Schwedt, Todd J., et al.
Publicado: (2018)

Effects of fremanezumab in patients with chronic migraine and comorbid depression: Subgroup analysis of the randomized HALO CM study
por: Lipton, Richard B., et al.
Publicado: (2021)

Adding acute treatments for patients on triptans: Results of the American Migraine Prevalence & Prevention (AMPP) study
por: Lipton, RB, et al.
Publicado: (2013)

Unmet Acute Treatment Needs From the 2017 Migraine in America Symptoms and Treatment Study
por: Lipton, Richard B., et al.
Publicado: (2019)

Consistency vs. switching triptan treatment and headache-related disability: Results of the American migraine prevalence & prevention study
por: Buse, DC, et al.
Publicado: (2013)

Systematic review of outcomes and endpoints in preventive migraine clinical trials
por: McGinley, James S., et al.
Publicado: (2021)

Systematic review of outcomes and endpoints in acute migraine clinical trials
por: Houts, Carrie R., et al.
Publicado: (2021)

FORWARD Study: Evaluating the Comparative Effectiveness of OnabotulinumtoxinA and Topiramate for Headache Prevention in Adults With Chronic Migraine
por: Rothrock, John F., et al.
Publicado: (2019)

Real-World Evidence for the Safety and Efficacy of CGRP Monoclonal Antibody Therapy Added to OnabotulinumtoxinA Treatment for Migraine Prevention in Adult Patients With Chronic Migraine
por: Mechtler, Laszlo, et al.
Publicado: (2022)

The Impact of OnabotulinumtoxinA vs. Placebo on Efficacy Outcomes in Headache Day Responder and Nonresponder Patients with Chronic Migraine
por: Silberstein, Stephen D., et al.
Publicado: (2020)

Effects of onabotulinumtoxinA treatment in chronic migraine patients with and without daily headache at baseline: results from the COMPEL Study
por: Young, William B., et al.
Publicado: (2019)

Mechanism of Action of OnabotulinumtoxinA in Chronic Migraine: A Narrative Review
por: Burstein, Rami, et al.
Publicado: (2020)

Comorbidities of Migraine
por: Wang, Shuu-Jiun, et al.
Publicado: (2010)

Burden of Illness Among People with Migraine and ≥ 4 Monthly Headache Days While Using Acute and/or Preventive Prescription Medications for Migraine
por: Buse, Dawn C., et al.
Publicado: (2020)

Pathophysiology of migraine
por: Goadsby, Peter J.
Publicado: (2012)

Improving the detection of chronic migraine: Development and validation of Identify Chronic Migraine (ID-CM)
por: Lipton, Richard B, et al.
Publicado: (2015)

The migraine postdrome: An electronic diary study
por: Giffin, Nicola J., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_ngrs5mkdkd1dgo8rqtv43drci1